Clinical trial
A Phase 3, Randomized, Open-Label Study to Evaluate the Efficacy and Safety of AMZ002, Compared to Vigabatrin, in the Treatment of Infantile Spasms
NCT05128344 is registered in ClinicalTrials.gov with Amzell as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Phase 3, Randomized, Open-Label Study to Evaluate the Efficacy and Safety of AMZ002, Compared to Vigabatrin, in the Treatment of Infantile Spasms
- Lead sponsor
- Amzell
- Phase
- Phase 3
- Overall status
- Withdrawn
- Start date
- April 30, 2023
- Completion date
- December 31, 2025
- Enrollment
- 0 (actual)
- Sites
- 41
Conditions
As the registry lists them; a condition with its own page is linked.